Let's focus on what we can do!

Facebook Twitter Instagram Linkedin
What are you looking for?

By Disabled People for Disabled People

  • Home
  • >
  • Latest Headlines
  • >
  • FDA Rejects PTC’s New Drug Application for Translarna as a Nonsense Mutation DMD Treatment – Muscular Dystrophy News
Friday, 26 February, 2016

Categories

FDA Rejects PTC’s New Drug Application for Translarna as a Nonsense Mutation DMD Treatment – Muscular Dystrophy News

Ataluren is a small-molecule protein restoration therapy compound in clinical development for the treatment of Duchenne muscular dystrophy (DMD) caused by a nonsense mutation (nmDMD), cystic fibrosis caused by a nonsense mutation (nmCF), and other …

Read More

Source:FDA Rejects PTC’s New Drug Application for Translarna as a Nonsense Mutation DMD Treatment – Muscular Dystrophy News

Categories :
  • Latest Headlines , 
  • Muscular Dystrophy , 
  • Uncategorized
Socials :

Recent posts

@abilitytoday
Let's share our
memories
@abilitytodayuk
Let's be
friends
@abilitytoday
Let's chat and hear
your voice
@ability-today
Let's get down to
Business
ABILITY TODAY TO YOUR INBOX

By clicking “SUBSCRIBE NOW,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.

Our Awards and Partners

NCTJ Logo
AccessiBe Logo
UnLtd Logo
BeyondWords Logo
The Shaw Trust Logo
Social Enterprise UK
Community Fund Logo
Disability confident Logo
Lotus Awards Logo
NCTJ - Quality, Trust and Diversity in Journalism
Donate to DisAbility Today CIC
t/a Ability Today
(A Social Enterprise)

Copyright © 2023 All rights reserved                  DisAbility Today CIC t/a Ability Today CIC

Facebook Twitter Instagram Linkedin

Student Profiles Coming Soon...